Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market®
September 27, 2021 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 20, 2021 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)
August 26, 2021 07:00 ET
|
Anavex Life Sciences Corp.
Published in Scientific Reports, Results Highlight Reversal of Hyperactivity and Restoration of Associative Learning and Reduction of Anxiety, Phenotypes Associated with Fragile X Syndrome Positron...
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results
August 12, 2021 07:00 ET
|
Anavex Life Sciences Corp.
Total of 509 Patients Enrolled in Confirmatory Late-stage Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s DiseaseExceeding of Enrollment Target for...
Anavex Life Sciences to Announce Fiscal 2021 Third Quarter Financial Results on Thursday, August 12, 2021
August 05, 2021 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021
August 04, 2021 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease
July 29, 2021 07:00 ET
|
Anavex Life Sciences Corp.
Pre-Treatment with ANAVEX®2-73 entirely prevented Abeta-induced cognitive decline Anavex planning a Phase 3 prevention trial of ANAVEX®2-73 including participants at risk for cognitive and functional...
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia
June 28, 2021 07:00 ET
|
Anavex Life Sciences Corp.
ANAVEX®2-73 treatment resulted in significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the primary and secondary clinical efficacy...
Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering
June 24, 2021 16:15 ET
|
Anavex Life Sciences Corp.
NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...